Non-Injectable Insulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Pills, Sprays, and Others), By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores), By Region and Competition, 2020-2030F
Market Overview
The Global Non-Injectable Insulin Market was valued at USD 3.14 Billion in 2024 and is projected t%li%reach USD 5.45 Billion by 2030, growing at a CAGR of 9.63% during the forecast period. This market encompasses insulin formulations designed t%li%be administered without needles, offering alternatives t%li%traditional injection-based delivery. Non-injectable insulin options—such as oral pills, inhalable forms, sprays, and patches—are being developed t%li%improve patient adherence and quality of life, especially for individuals wh%li%face challenges with injections. These delivery systems aim t%li%offer a more user-friendly experience while maintaining effective blood glucose control. Despite the promise, the market faces hurdles due t%li%clinical setbacks; for instance, Oramed Pharmaceuticals' oral insulin candidate ORMD-0801 failed t%li%meet its primary endpoint, and Biocon halted a Phase 1 trial of Tregopil for Type 1 diabetes. However, with continued innovation and patient-centric product development, non-injectable insulin therapies are expected t%li%gain traction as a viable alternative for diabetes management.
Key Market Drivers
Improved Glycemic Control
Enhanced glycemic control is a pivotal driver of growth in the Global Non-Injectable Insulin Market. Traditional injectable insulin can be uncomfortable, often leading t%li%poor compliance. Non-injectable delivery systems address this by offering less invasive options, improving patient adherence and reducing anxiety associated with needle use. These alternatives als%li%support earlier initiation of insulin therapy, allowing better management of blood glucose levels and delaying the progression of diabetes-related complications. By accommodating patients with physical limitations or needle aversion, these technologies increase treatment accessibility and improve health outcomes. The availability of user-friendly insulin forms als%li%encourages adoption among previously reluctant patient populations, thereby expanding the market base and accelerating growth.
Key Market Challenges
Efficacy and Safety Concerns
Concerns over the effectiveness and safety of non-injectable insulin continue t%li%hinder broader market adoption. While these alternatives promise improved convenience, they must demonstrate clinical efficacy equivalent t%li%traditional injections t%li%gain widespread acceptance. Issues such as variable absorption rates and inconsistent glucose control can create doubts among healthcare professionals. Furthermore, the potential for unknown long-term side effects associated with newer delivery technologies adds t%li%skepticism. Regulatory bodies require robust evidence t%li%approve such therapies, and without it, product launches may be delayed or restricted. This uncertainty affects physician confidence and limits patient uptake, ultimately restraining market expansion.
Key Market Trends
Personalized Treatment Approaches
The growing trend toward personalized medicine is significantly shaping the Global Non-Injectable Insulin Market. Tailoring treatment strategies t%li%individual patient needs—considering factors like lifestyle, age, comorbidities, and psychological preferences—enhances therapy adherence and outcomes. Non-injectable insulin options provide flexibility that supports this personalization. For instance, oral formulations may better suit elderly patients with dexterity issues, while sprays may appeal t%li%younger demographics seeking ease and discretion. Customized treatment protocols that incorporate these delivery systems can minimize patient discomfort and improve disease management. This trend aligns with the broader healthcare movement toward patient-centered care and is expected t%li%contribute significantly t%li%the market’s long-term growth.
Key Market Players
In this report, the Global Non-Injectable Insulin Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Non-Injectable Insulin Market.
Available Customizations:
Global Non-Injectable Insulin Market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
The Global Non-Injectable Insulin Market was valued at USD 3.14 Billion in 2024 and is projected t%li%reach USD 5.45 Billion by 2030, growing at a CAGR of 9.63% during the forecast period. This market encompasses insulin formulations designed t%li%be administered without needles, offering alternatives t%li%traditional injection-based delivery. Non-injectable insulin options—such as oral pills, inhalable forms, sprays, and patches—are being developed t%li%improve patient adherence and quality of life, especially for individuals wh%li%face challenges with injections. These delivery systems aim t%li%offer a more user-friendly experience while maintaining effective blood glucose control. Despite the promise, the market faces hurdles due t%li%clinical setbacks; for instance, Oramed Pharmaceuticals' oral insulin candidate ORMD-0801 failed t%li%meet its primary endpoint, and Biocon halted a Phase 1 trial of Tregopil for Type 1 diabetes. However, with continued innovation and patient-centric product development, non-injectable insulin therapies are expected t%li%gain traction as a viable alternative for diabetes management.
Key Market Drivers
Improved Glycemic Control
Enhanced glycemic control is a pivotal driver of growth in the Global Non-Injectable Insulin Market. Traditional injectable insulin can be uncomfortable, often leading t%li%poor compliance. Non-injectable delivery systems address this by offering less invasive options, improving patient adherence and reducing anxiety associated with needle use. These alternatives als%li%support earlier initiation of insulin therapy, allowing better management of blood glucose levels and delaying the progression of diabetes-related complications. By accommodating patients with physical limitations or needle aversion, these technologies increase treatment accessibility and improve health outcomes. The availability of user-friendly insulin forms als%li%encourages adoption among previously reluctant patient populations, thereby expanding the market base and accelerating growth.
Key Market Challenges
Efficacy and Safety Concerns
Concerns over the effectiveness and safety of non-injectable insulin continue t%li%hinder broader market adoption. While these alternatives promise improved convenience, they must demonstrate clinical efficacy equivalent t%li%traditional injections t%li%gain widespread acceptance. Issues such as variable absorption rates and inconsistent glucose control can create doubts among healthcare professionals. Furthermore, the potential for unknown long-term side effects associated with newer delivery technologies adds t%li%skepticism. Regulatory bodies require robust evidence t%li%approve such therapies, and without it, product launches may be delayed or restricted. This uncertainty affects physician confidence and limits patient uptake, ultimately restraining market expansion.
Key Market Trends
Personalized Treatment Approaches
The growing trend toward personalized medicine is significantly shaping the Global Non-Injectable Insulin Market. Tailoring treatment strategies t%li%individual patient needs—considering factors like lifestyle, age, comorbidities, and psychological preferences—enhances therapy adherence and outcomes. Non-injectable insulin options provide flexibility that supports this personalization. For instance, oral formulations may better suit elderly patients with dexterity issues, while sprays may appeal t%li%younger demographics seeking ease and discretion. Customized treatment protocols that incorporate these delivery systems can minimize patient discomfort and improve disease management. This trend aligns with the broader healthcare movement toward patient-centered care and is expected t%li%contribute significantly t%li%the market’s long-term growth.
Key Market Players
- Midatech Pharma Plc
- Shreya Life Sciences Pvt. Ltd.
- Boston Therapeutics, Inc.
- Coromed, Inc.
- Diabetology Ltd.
- Emisphere Technologies, Inc.
- Oramed Pharmaceuticals, Inc.
- Diasome Pharmaceuticals, Inc.
- Generex Biotechnology Corp.
- Biodel, Inc.
In this report, the Global Non-Injectable Insulin Market has been segmented int%li%the following categories, in addition t%li%the industry trends which have als%li%been detailed below:
- Non-Injectable Insulin Market, By Product:
- Pills
- Sprays
- Others
- Non-Injectable Insulin Market, By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Drug Stores
- Non-Injectable Insulin Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Non-Injectable Insulin Market.
Available Customizations:
Global Non-Injectable Insulin Market report with the given market data, TechSci Research offers customizations according t%li%a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up t%li%five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NON-INJECTABLE INSULIN MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Pills, Sprays, and Others)
5.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.4. By Company (2024)
5.3. Market Map
5.3.1. By Product
5.3.2. By Distribution Channel
5.3.3. By Region
6. NORTH AMERICA NON-INJECTABLE INSULIN MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-Injectable Insulin Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Distribution Channel
6.3.2. Canada Non-Injectable Insulin Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Distribution Channel
6.3.3. Mexico Non-Injectable Insulin Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Distribution Channel
7. EUROPE NON-INJECTABLE INSULIN MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Non-Injectable Insulin Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Distribution Channel
7.3.2. Germany Non-Injectable Insulin Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Distribution Channel
7.3.3. United Kingdom Non-Injectable Insulin Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Distribution Channel
7.3.4. Italy Non-Injectable Insulin Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Distribution Channel
7.3.5. Spain Non-Injectable Insulin Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Distribution Channel
8. ASIA-PACIFIC NON-INJECTABLE INSULIN MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Non-Injectable Insulin Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Distribution Channel
8.3.2. India Non-Injectable Insulin Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Distribution Channel
8.3.3. Japan Non-Injectable Insulin Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Distribution Channel
8.3.4. South Korea Non-Injectable Insulin Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Distribution Channel
8.3.5. Australia Non-Injectable Insulin Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Distribution Channel
9. SOUTH AMERICA NON-INJECTABLE INSULIN MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Non-Injectable Insulin Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Distribution Channel
9.3.2. Argentina Non-Injectable Insulin Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Distribution Channel
9.3.3. Colombia Non-Injectable Insulin Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Distribution Channel
10. MIDDLE EAST AND AFRICA NON-INJECTABLE INSULIN MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Non-Injectable Insulin Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Distribution Channel
10.3.2. Saudi Arabia Non-Injectable Insulin Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Distribution Channel
10.3.3. UAE Non-Injectable Insulin Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. GLOBAL NON-INJECTABLE INSULIN MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Midatech Pharma Plc
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.2. Product Offerings
15.1.3. Recent Developments
15.1.4. Financials (As Reported)
15.1.5. Key Personnel Details
15.1.6. SWOT Analysis
15.2. Shreya Life Sciences Pvt. Ltd.
15.3. Boston Therapeutics, Inc.
15.4. Coromed, Inc.
15.5. Diabetology Ltd.
15.6. Emisphere Technologies, Inc.
15.7. Oramed Pharmaceuticals, Inc.
15.8. Diasome Pharmaceuticals, Inc.
15.9. Generex Biotechnology Corp.
15.10. Biodel, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NON-INJECTABLE INSULIN MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Pills, Sprays, and Others)
5.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.4. By Company (2024)
5.3. Market Map
5.3.1. By Product
5.3.2. By Distribution Channel
5.3.3. By Region
6. NORTH AMERICA NON-INJECTABLE INSULIN MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-Injectable Insulin Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Distribution Channel
6.3.2. Canada Non-Injectable Insulin Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Distribution Channel
6.3.3. Mexico Non-Injectable Insulin Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Distribution Channel
7. EUROPE NON-INJECTABLE INSULIN MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Non-Injectable Insulin Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Distribution Channel
7.3.2. Germany Non-Injectable Insulin Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Distribution Channel
7.3.3. United Kingdom Non-Injectable Insulin Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Distribution Channel
7.3.4. Italy Non-Injectable Insulin Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Distribution Channel
7.3.5. Spain Non-Injectable Insulin Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Distribution Channel
8. ASIA-PACIFIC NON-INJECTABLE INSULIN MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Non-Injectable Insulin Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Distribution Channel
8.3.2. India Non-Injectable Insulin Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Distribution Channel
8.3.3. Japan Non-Injectable Insulin Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Distribution Channel
8.3.4. South Korea Non-Injectable Insulin Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Distribution Channel
8.3.5. Australia Non-Injectable Insulin Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Distribution Channel
9. SOUTH AMERICA NON-INJECTABLE INSULIN MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Non-Injectable Insulin Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Distribution Channel
9.3.2. Argentina Non-Injectable Insulin Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Distribution Channel
9.3.3. Colombia Non-Injectable Insulin Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Distribution Channel
10. MIDDLE EAST AND AFRICA NON-INJECTABLE INSULIN MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Non-Injectable Insulin Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Distribution Channel
10.3.2. Saudi Arabia Non-Injectable Insulin Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Distribution Channel
10.3.3. UAE Non-Injectable Insulin Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. GLOBAL NON-INJECTABLE INSULIN MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Midatech Pharma Plc
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.2. Product Offerings
15.1.3. Recent Developments
15.1.4. Financials (As Reported)
15.1.5. Key Personnel Details
15.1.6. SWOT Analysis
15.2. Shreya Life Sciences Pvt. Ltd.
15.3. Boston Therapeutics, Inc.
15.4. Coromed, Inc.
15.5. Diabetology Ltd.
15.6. Emisphere Technologies, Inc.
15.7. Oramed Pharmaceuticals, Inc.
15.8. Diasome Pharmaceuticals, Inc.
15.9. Generex Biotechnology Corp.
15.10. Biodel, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
